Advances in Leukemia invites submissions that advance understanding of leukemia biology, diagnostics, therapeutics, and patient outcomes.

We welcome studies across acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, and related hematologic malignancies.

Priority topics include precision oncology, targeted therapies, CAR-T and cellular therapies, stem cell transplantation, and resistance mechanisms.

We encourage submissions on biomarkers, genomics, immunophenotyping, minimal residual disease monitoring, and real-world outcomes.

We welcome manuscripts on leukemia survivorship, late effects, and quality-of-life outcomes.

Studies on health equity, access to therapies, and diagnostic delays are encouraged.

Submissions on bioinformatics, AI-driven diagnostics, and imaging analytics are in scope.

We welcome translational studies connecting molecular findings to clinical outcomes.

Submissions on CAR-T cell therapy optimization and toxicity management are encouraged.

Studies on minimal residual disease monitoring and prognostic biomarkers are in scope.

Papers on leukemia survivorship, quality of life, and late effects are welcome.

Real-world evidence and registry analyses strengthen clinical relevance.

We encourage submissions addressing health equity and access to leukemia care.

Manuscripts on pediatric leukemia and adolescent transitions are encouraged.

Studies on drug resistance mechanisms and novel targets are prioritized.

Systematic reviews should follow PRISMA and include search strategies.

Clinical trial reports should include CONSORT flow diagrams.

Observational studies should align with STROBE reporting guidelines.

Manuscripts should include clear ethics approvals and consent statements.

Data availability statements are required for all submissions.

Brief reports are considered when they provide novel clinical insights.

Genome-wide studies should provide accession numbers and dataset references.

We welcome multi-center collaborations and international cohort studies.

Submissions on supportive care and symptom management are encouraged.

Papers on hematologic malignancy diagnostics, imaging, and pathology are welcome.

Clear statistical reporting improves review efficiency and credibility.

All submissions receive expert peer review with clinical focus.

We encourage submissions on minimal residual disease and longitudinal monitoring strategies.

Studies on resistance pathways and treatment sequencing are in scope.

Manuscripts on transplantation outcomes and graft-versus-host disease are welcome.

We invite research on supportive care, infection management, and survivorship planning.

Submissions involving real-world data should describe data sources and limitations.

High-quality negative or neutral results are considered when methodologically sound.

Ensure ethical approvals and data privacy safeguards are clearly described.

Use consistent leukemia classification standards and definitions throughout the manuscript.

Provide clear clinical implications to guide practice and future research.

We welcome clinical trials evaluating new agents or combination therapies.

Manuscripts on disease biology, signaling pathways, and microenvironment are encouraged.

Submissions on diagnostic assay development and validation are within scope.

We invite studies on relapse prediction and therapeutic response biomarkers.

Papers on patient-reported outcomes and supportive care are welcome.

Preclinical studies should connect mechanistic insights to clinical relevance.

Provide clear endpoints and outcome definitions for all study designs.

Collaborative studies across institutions and registries are encouraged.

We value rigorous methodology and transparent data reporting.

Include trial registration numbers and ethics approvals where required.

High-impact reviews and meta-analyses should include robust methodology.

We invite submissions on leukemia genomics, epigenetics, and clonal evolution.

Studies on minimal residual disease detection and monitoring are encouraged.

Manuscripts addressing therapy-related toxicities and mitigation strategies are welcome.

Clinical studies should describe inclusion criteria, endpoints, and follow-up duration.

Submissions on disease modeling and translational pipelines are in scope.

Reports on health systems and care pathways can improve clinical translation.

We welcome cohort studies with clear statistical analysis plans.

Submissions should articulate clinical significance and practice implications.

Use recognized reporting frameworks such as CONSORT, STROBE, PRISMA, or REMARK when applicable.

Include ethics approvals, consent statements, and trial registrations for clinical studies.

Provide a structured abstract with key outcomes, effect sizes, and clinical interpretation.

Ensure figures and tables are clear, de-identified, and aligned with the results narrative.